ImmunityBio, Inc. (IBRX) reported significant revenue growth with total revenue reaching $113.3 million in 2025, a 668% increase from $14.7 million in 2024. This surge in revenue is primarily driven by the commercialization of Anktiva (nogapendekin alfa inbakicept), which is approved in the U.S. for adults with BCG-unresponsive non-muscle invasive bladder cancer and launched following FDA approval in April 2024. The first quarter of 2026 marked further growth, with revenue of $44.2 million, up 168% year over year.
Anktiva has also gained conditional approval in the European Union and the United Kingdom as well as in Saudi Arabia, expanding its addressable market. A key upcoming regulatory milestone is an FDA decision anticipated by January 6, 2027, regarding Anktiva’s use in BCG-unresponsive NMIBC with papillary-only disease.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
